Form 4: ARS Pharmaceuticals Director, Brent L Saunders, Acquires 40,000 Stock Options
SEC Form 4 Filing
Brent L Saunders, a director at ARS Pharmaceuticals, acquired 40,000 stock options on June 20, 2024, exercisable at $7.73, vesting on June 20, 2025, or the date of the 2025 annual meeting.
Summary
- On June 20, 2024, Brent L Saunders, a director of ARS Pharmaceuticals, Inc. (SPRY), acquired 40,000 stock options.
- The exercise price of these options is $7.73.
- The options vest fully on the earlier of June 20, 2025, or the date of the Issuer's 2025 annual meeting of stockholders.
- The options expire on June 19, 2034.
Sentiment
Score: 5
Explanation: The document is a standard regulatory filing related to stock option grants, indicating a neutral sentiment.
Industry Context
This filing is a routine disclosure of stock option grants to a company director, which is a common practice in publicly traded companies to align management's interests with those of shareholders.
Stakeholder Impact
- The granting of stock options to a director can align their interests with those of shareholders, potentially incentivizing them to increase shareholder value.
Key Dates
| Date | Description |
|---|---|
| 06/20/2024 | Date of the transaction: acquisition of 40,000 stock options. |
| 06/20/2025 | Vesting date of the stock options, or the date of the 2025 annual meeting, whichever is earlier. |
| 06/19/2034 | Expiration date of the stock options. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.